The Path to Paxlovid.

ACS Cent Sci

Published: April 2022

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052793PMC
http://dx.doi.org/10.1021/acscentsci.2c00369DOI Listing

Publication Analysis

Top Keywords

path paxlovid
4
path
1

Similar Publications

Article Synopsis
  • The Edisonian approach to drug development, which involves trial and error, struggles with the risk of creating ineffective or harmful drugs, particularly against emerging pandemics like COVID-19, due to limitations in current antiviral treatments and the challenges posed by declining birth rates and an aging workforce in science.* ! -
  • Despite some existing antivirals (Remdesivir, Molnupiravir, Paxlovid) showing moderate effectiveness, there's a critical need for new antiviral drugs and advanced technology to effectively target and disable the coronavirus’s proteins.* ! -
  • Research efforts focus on creating innovative drug candidates by designing compounds that follow Lipinski's rule of druglikeness but with fewer rotational bonds to enhance their ability to inhibit viral
View Article and Find Full Text PDF

The antiviral drug Paxlovid has been shown to rapidly reduce viral load. Coupled with vaccination, timely administration of safe and effective antivirals could provide a path towards managing COVID-19 without restrictive non-pharmaceutical measures. Here, we estimate the population-level impacts of expanding treatment with Paxlovid in the US using a multi-scale mathematical model of SARS-CoV-2 transmission that incorporates the within-host viral load dynamics of the Omicron variant.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!